AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.
Peripheral T-cell Lymphoma Targeted Therapy
DRUG: Azacitidine|DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Epirubicin|DRUG: Vincristine|DRUG: Prednisone
Progression-free survival (PFS), Up to 1 year
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.